Skip to content
COMPANY
PRODUCTS
R & D
Product Candidates Overview
Pipeline
Orphan Drug Designations
PARTNERING
INVESTOR RELATIONS
Press Releases
Events & Presentations
Stock Information
SEC Filings
XBRL Filings
Stockholder Meeting
Corporate Governance
Email Alerts
Investor Contact
BLOG
CONTACT
Press Releases
Hemispherx Biopharma Launches New Website
Hemispherx Disseminates New Clinical Data on Experimental Treatment of Multi-Drug Resistant HIV/AIDS Virus Virus Levels Observed to Drop
Hemispherx Announces Poly I:Poly C12U Increases the Control of HIV During Strategic Treatment Interruption in Chronically HIV Infected Patients
Hemispherx to Present New Clinical Data on Experimental Treatment of Multi-Resistant HIV/AIDS Virus
Hemispherx Defamation Trial Results in Claims of Both Parties Being Denied Jury Fails To Award Damages Against Asensio;
Hemispherx Continues To Enroll New Clinical Investigators And Expand Clinical Trial Sites In HIV Trials Company Also Prepares To Present At Upcoming Scientific Conferences
Hemispherx Comments on New Report From U.S. Agency for Healthcare Research and Quality -- AHRQ -- on Chronic Fatique Syndrome -- CFS --
HEMISPHERx ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
Hemispherx Biopharma Will Announce New HIV Clinical Treatment Data On Immune Intervention during "Drug Holidays" at WHO Conference
Hemispherx Awarded U.S. Patent on Novel Fusion Inhibitor of HIV
77
78
79
80
81
82
83
<<
<
>
>>
Privacy